Beauregard, Jean-Mathieu

Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial

Del Prete, M., Buteau, F.-A., Arsenault, F., Saighi, N., Bouchard, L.-O., Beaulieu, A., & Beauregard, J.-M. (2019) · European Journal of Nuclear Medicine and Molecular Imaging

Neuroendocrine Tumor Research AdvancesRadiopharmaceutical Chemistry and Applications

Cited by 184

Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial

Fizazi, K., Herrmann, K., Krause, B. J., Rahbar, K., Chi, K. N., Morris, M. J., Sartor, O., Tagawa, S. T., Kendi, A. T., Vogelzang, N., et al. (2023) · The Lancet Oncology

Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications

Cited by 125

Role of Artificial Intelligence in Theranostics

Brosch-Lenz, J., Yousefirizi, F., Zukotynski, K., Beauregard, J.-M., Gaudet, V., Saboury, B., Rahmim, A., & Uribe, C. (2021) · PET Clinics

Radiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and Applications

Cited by 42

Clinical impact of a second FDG-PET in atypical/unclear dementia syndromes

Bergeron, D., Beauregard, J.-M., Guimond, J., Fortin, M.-P., Houde, M., Poulin, S., Verret, L., Bouchard, R. W., & Laforce, R. (2015) · Journal of Alzheimer's Disease

Dementia and Cognitive Impairment ResearchMedical Imaging Techniques and Applications

Cited by 17